Navigation Links
Variation in make-up of generic epilepsy drugs can lead to dosing problems
Date:6/30/2011

Generic anti-epilepsy drugs, pharmaceutical products similar to brand-name versions, save consumers billions of dollars each year, but some are different enough from branded formulations that they may not be effective, particularly if patients switch between two generic drugs, a new study by Johns Hopkins researchers suggests.

A report on the study, published online and in an upcoming issue of Annals of Neurology, raises questions about whether some generic products are safe and effective when a narrow dose range separates patients from help and harm.

"In most areas of medicine, generics work well and are an incredible savings for health plans and patients," explains study leader Gregory Krauss, M.D., professor of neurology at the Johns Hopkins University School of Medicine. However, he adds, epilepsy patients whose condition is well-controlled on brand-name medications often worry that switching to generic versions might change blood medication levels, leading to seizures and side effects. These fears aren't without merit; studies have shown that patients frequently complain of breakthrough seizures when switched to generic drugs.

Consequently, Krauss and his colleagues decided to compare how generics stack up to their brand-name counterparts, as well as other generic formulations for the same drug, using the bioequivalence study data that generic manufacturers generate to gain U.S. Food and Drug Administration (FDA) approval. Such data, held privately by the FDA, are mandated by the Drug Price Competition and Patent Term Restoration Act (informally known as the Hatch-Waxman Act). Part of this law, passed during the Reagan administration, states that generic formulations must have a peak blood concentration and total amount absorbed that falls between 80 percent and 125 percent of the name-brand version.

That range is suitable for the vast majority of pharmaceuticals, says Krauss. However, he notes, for some "critical dose" drugs that have a high potential for over- or underdosing, the window could be significantly narrower.

After securing bioequivalency data for 141 generic epilepsy drugs from the FDA using Freedom of Information Act requests, Krauss and his colleagues found that peak blood concentration and total amount absorbed differed by less than 15 percent between the vast majority of generics and their brand-name equivalents. However, some manufacturers had generic products that were at the upper or lower edge of the acceptance limits, and these drugs varied markedly between each other compared to the brand-name drugs-as much as 30 percent between generic formulations for one drug in particular, oxycarbazepine.

Since each brand-name drug can have many different generic counterparts - and pharmacies frequently switch between different generic versions - prescriptions for some generic drugs could prove unsafe for epilepsy patients, Krauss notes.

"Overall, generics should be used for treating epilepsy," Krauss says. "However, we suggest that patients and pharmacies should be cautious when switching between different generic version of anticonvulsants, and policy makers should evaluate whether standards that set the range for generics' similarity to brand name versions are appropriate for every drug. For patients with epilepsy, that may not be the case."

He notes that for other pharmaceuticals in which over- or underdosing by narrow margins may also be a problem, such as chemotherapeutics for cancer, the same questions can be raised.


'/>"/>

Contact: Christen Brownlee
cbrownlee@jhmi.edu
410-955-7832
Johns Hopkins Medical Institutions
Source:Eurekalert

Related medicine news :

1. Gene Variation May Explain Some Female Infertility Cases
2. Gene variation linked to infertility in women, study finds
3. MicroRNA variations associated with earlier prostate cancer diagnosis in African-American men
4. Genetic variation linked to longer telomeres and lower risk of bladder cancer
5. Genetic variation cuts bladder cancer risk, protects chromosome tips
6. ICUROS study finds international variations in quality of life loss after fracture
7. Gene Variation Linked to Altruism
8. Regional variation in health-care spending and utilization higher in Medicare than private sector
9. Chromosomal variations found in early passage female embryonic stem cells
10. Three Genes Linked to Variations in Eye Color
11. 9-country study shows wide variations in how women with early breast cancer are treated
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/27/2016)... , ... May 27, 2016 , ... This campaign aims ... stroke, which we as a society can control and change. , As nearly 795,000 ... every 40 seconds within the United States. Plus, with an estimated 129,000 of these ...
(Date:5/27/2016)... ... May 27, 2016 , ... Aimed at nurses and ... interest stories, courtesy of leaders in the nursing and health care industry. It ... leading advocates and associations—namely Jones & Bartlett Learning. , Jones & Bartlett Learning ...
(Date:5/26/2016)... ... May 26, 2016 , ... Despite last week’s media reports ... Yellen and company to wait until March 2017 for an interest rate increase, according ... Robinson College of Business. , “The Federal Open Market Committee (FOMC) dot charts are ...
(Date:5/26/2016)... St. Louis, Missouri (PRWEB) , ... May 26, ... ... optimal cost, quality and clinical outcomes, hosted members and suppliers for its inaugural ... with a focus on their mission of elevating the operational health of America’s ...
(Date:5/26/2016)... ... ... The Woodlands at John Knox Village , Florida’s first Life Plan ... and healing, celebrated its grand opening, today. The Woodlands at John Knox Village is ... Staff. , “This is an incredibly fulfilling time for John Knox Village as we ...
Breaking Medicine News(10 mins):
(Date:5/24/2016)... 2016 Niederländische Chirurgen haben ... es Ärzten erlaubt, ihre Expertise weltweit zu teilen ... Live Streaming mit einer Instant-Messaging-Funktion und der Möglichkeit, ... in Europa, Afrika, Asien und den ... Plattform registriert. Information und Weiterbildung   ...
(Date:5/24/2016)... May 24, 2016  Diana Russell suffers from a ... from the inside out.  This disease has put her ... her children and grandchildren to leave her home.  Because ... family cannot haul the wheelchair.  So if there is ... and Diana is left to wait for the bus. ...
(Date:5/24/2016)...  Joe Marziani has joined VMS BioMarketing as senior vice president of sales, announced ... new role, Marziani will lead the company,s business development and sales team, exploring new ... Photo - http://photos.prnewswire.com/prnh/20160523/371089 ... ... ...
Breaking Medicine Technology: